Crystal engineering as application of concept of supramolecular synthesis to generate the multiple-component crystalline phases represents an effective way to modify known active pharmaceutical ingredients and to improve its pharmaceutical profile [1]. Carboxylic acid-pyridine synthon has emerged as a reliable tool in design of molecular complexes of dicarboxylic acids with isonicotine amide [2]. We have utilized this approach as recurring design strategy in supramolecular synthesis of solid state composition of pharmaceutical phases. Isonicotinic acid hydrazide (INH) is used as a first-line treatment for tuberculosis, in combination with other drugs for the treatment of active disease and also used for prevention of tuberculosis in people who have been exposed to active disease. Crystallizations of INH with dicarboxylic acids resulted in six INH:dicarboxylic acid supramolecular systems: 2:1 co-crystals of with malonic, succinic and adipic acids, co-crystals 1:1 with glutaric acid and 1:1 organic salts with oxalic and D-tartaric acids. In co-crystals adipic, succinic and malonic acids invariably form acid – pyridine O-H···N hydrogen bond synthons with two neighboring INH molecules, glutaric acid forms different acid-pyridine and acid-hydrazide syntons. Malonic acid···INH strong O-H···N bonds (O···N=2.527Å, O-H=1.217Å, H···N=1.316Å) demonstrate the case of partial proton transfer. In the structure of INH : oxalic acid the INH molecules are doubly protonated on aromatic nitrogen and terminal aminogroup and alternate in the charge assisted N-H···O-bonded zigzag chain with oxalate di-anions. Acid-pyridine synthon has not been found in the structure of INH : D-Tartaric acid, but bifurcated N-H···O/N-H···N bonds unite protonated on basic nitrogen INH in the chains.